Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Idexx Laboratories (IDXX)

IDEXX Laboratories adopts nonqualified deferred compensation plan for select employees

Neutral Impact 2 of 5 shareholder Written later

IDEXX's board approved a new unfunded deferred compensation plan on December 6, 2024, letting select management and highly compensated employees defer part of their pay. The filing describes the plan's terms but gives no financial figures for its cost or expected size, and it is a compensation arrangement rather than a change in leadership.

Key points

  • Board approved the IDEXX Deferred Compensation Plan on December 6, 2024, on the Compensation and Talent Committee's recommendation.
  • Participants may defer 5% to 50% of base salary and 5% to 100% of annual bonus and stock units.
  • The Company has no current intention to make discretionary contributions to participant accounts.
  • Full plan document will be filed as an exhibit to the 2024 Form 10-K.

The filing

CompanyIdexx Laboratories (IDXX)
Form8-K, current report
Filed with the SECDec 12, 2024, 4:00 PM ET
Accession number0000874716-24-000150

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 12, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.